用途
适用于以白炭黑或硅酸盐等为补强剂的硫化橡胶体系。这是一种已经在橡胶工业中成功应用的多官能团有机硅偶联剂。其主要作用在于提高橡胶的弹性模量和抗拉强度,显著改善橡胶的耐磨性能和压缩性能,同时降低橡胶粘度,节约加工能耗。该产品特别适用于含双键聚合物或其共混物中的配方,尤其是那些采用含有羟基填料(如白炭黑、硅酸盐等)的天然橡胶(NR)、丁苯橡胶(SBR)、异戊二烯橡胶(IR)、丁二烯橡胶(BR)、丁腈橡胶(NBR)和三元乙丙橡胶(EPDM)。与40372-72-3相比,由于本品具有较低活性的二硫烷官能团,因此可以提供更可靠的焦烧安全性。
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
3-巯丙基三乙氧基硅烷 | 3-Mercaptopropyltriethoxysilane | 14814-09-6 | C9H22O3SSi | 238.423 |
双-[3-(三乙氧基硅)丙基]-四硫化物 | bis(3-triethoxysilylpropyl) tetrasulfide | 40372-72-3 | C18H42O6S4Si2 | 538.963 |
3-氯丙基三乙氧基硅烷 | (3-chloropropyl)triethoxysilane | 5089-70-3 | C9H21ClO3Si | 240.802 |
烯丙基三乙氧基硅烷 | allyltriethoxysilane | 2550-04-1 | C9H20O3Si | 204.341 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
3-巯丙基三乙氧基硅烷 | 3-Mercaptopropyltriethoxysilane | 14814-09-6 | C9H22O3SSi | 238.423 |
4,4,14,14-四乙氧基-3,15-二氧杂-8,9,10-三硫杂-4,14-二硅杂十七烷 | Bis-(3-triethoxysilylpropyl)trisulfid | 56706-11-7 | C18H42O6S3Si2 | 506.897 |
双-[3-(三乙氧基硅)丙基]-四硫化物 | bis(3-triethoxysilylpropyl) tetrasulfide | 40372-72-3 | C18H42O6S4Si2 | 538.963 |
—— | 2-[3-[3-[2-(dimethylamino)ethoxy-diethoxysilyl]propyldisulfanyl]propyl-diethoxysilyl]oxy-N,N-dimethylethanamine | 1184663-77-1 | C22H52N2O6S2Si2 | 560.968 |
三乙氧基-[3-(3-三乙氧基硅烷基丙基硫基)丙基]硅烷 | bis(triethoxysilylpropyl)sulfide | 60764-86-5 | C18H42O6SSi2 | 442.765 |
—— | bis(silatranylpropyl) disulfide | 883794-93-2 | C18H36N2O6S2Si2 | 496.797 |
3-氯丙基三乙氧基硅烷 | (3-chloropropyl)triethoxysilane | 5089-70-3 | C9H21ClO3Si | 240.802 |
3-辛酰基硫代丙基三乙氧基硅烷 | 3-octanoylthio-1-propyltriethoxysilane | 220727-26-4 | C17H36O4SSi | 364.622 |
Calcium overload and ROS overproduction, two major triggers of acute kidney injury (AKI), are self‐amplifying and mutually reinforcing, forming a complicated cascading feedback loop that induces kidney cell “suicide” and ultimately renal failure. There are currently no clinically effective drugs for the treatment of AKI, excluding adjuvant therapy. In this study, a porous silicon‐based nanocarrier rich in disulfide bond skeleton (<50 nm) is developed that enables efficient co‐loading of the hydrophilic drug borane amino complex and the hydrophobic drug BAPTA‐AM, with its outer layer sealed by the renal tubule‐targeting peptide PEG‐LTH. Once targeted to the kidney injured site, the nanocarrier structure collapses in the high glutathione environment of the early stage of AKI, releasing the drugs. Under the action of the slightly acidic inflammatory environment and intracellular esterase, the released drugs produce hydrogen and BAPTA, which can rapidly eliminate the excess ROS and overloaded Ca2+, blocking endoplasmic reticulum/mitochondrial apoptosis pathway (ATF4‐CHOP‐Bax axis, Casp‐12‐Casp‐3 axis, Cyt‐C‐Casp‐3 axis) and inflammatory pathway (TNF‐α‐NF‐κB axis) from the source, thus rescuing the renal cells in the “critical survival” state and further restoring the kidney function. Overall, this nanoparticle shows substantial clinical promise as a potential therapeutic strategy for I/R injury‐related diseases.
Visible light induced desulfurization–deuteration method was developed using D2O as the source of deuterium atoms. This radical approach features mild conditions, broad substrate scope, highly efficient D-incorporation and excellent functional group compatibility.